WO2024049279A2 - Microsphères à libération prolongée contenant du leuprolide, préparation injectable les comprenant, et leur procédé de préparation - Google Patents

Microsphères à libération prolongée contenant du leuprolide, préparation injectable les comprenant, et leur procédé de préparation Download PDF

Info

Publication number
WO2024049279A2
WO2024049279A2 PCT/KR2023/013112 KR2023013112W WO2024049279A2 WO 2024049279 A2 WO2024049279 A2 WO 2024049279A2 KR 2023013112 W KR2023013112 W KR 2023013112W WO 2024049279 A2 WO2024049279 A2 WO 2024049279A2
Authority
WO
WIPO (PCT)
Prior art keywords
microspheres
leuprolide
injectable preparation
sustained
release
Prior art date
Application number
PCT/KR2023/013112
Other languages
English (en)
Korean (ko)
Inventor
이진우
김보연
이주한
설은영
이희용
Original Assignee
주식회사 지투지바이오
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020230059471A external-priority patent/KR20240031868A/ko
Application filed by 주식회사 지투지바이오 filed Critical 주식회사 지투지바이오
Publication of WO2024049279A2 publication Critical patent/WO2024049279A2/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • the present invention relates to sustained-release microspheres containing leuprolide, an injectable preparation containing the same, a method for producing the same, and a pharmaceutical composition containing the sustained-release microspheres.
  • sustained-release microspheres that contain a high content of leuprolide in the microspheres and exhibit effective drug release characteristics initially while providing stable drug release characteristics for a long period of time, and a method of producing the same, the leuprolide It relates to an injectable preparation containing sustained-release microspheres containing Lyde.
  • Luteinizing hormone-releasing hormone also known as gonadotropin-releasing hormone (GnRH)
  • GnRH gonadotropin-releasing hormone
  • pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg- a hypothalamic decapeptide that regulates the reproductive system in vertebrates. Pro-Gly-NH 2 ).
  • LHRH agonists and antagonists are used for the treatment of endometriosis, fibroids, polycystic ovary, breast, ovarian and endometrial cancer in women, gonadotropic pituitary desensitization during medically assisted birth protocols, benign prostate and polymorphism and prostate cancer in men. It is reported to be effective in the treatment of and treatment of precocious puberty in men or women.
  • LHRH agonists are peptide compounds that generally must be administered via injection due to low oral bioavailability.
  • LHRH agonists are drugs for chronic diseases that require long-term administration, and that early and rapid exposure to a sufficient amount of the drug is required for drug efficacy to manifest. It is known that for the drug efficacy of leuprolide acetate, one of the LHRH agonists, to be expressed, a sufficient amount of drug exposure to the target area is required at the beginning of administration, and it is known that it is desirable to have a high initial drug release rate.
  • the present invention was designed to solve the above-described conventional problems. It can contain a high content of leuprolide in the microspheres, and not only exhibits effective drug release characteristics initially, but also provides stable drug release characteristics for a long period of time.
  • the purpose is to provide sustained-release microspheres containing a high content of leuprolide that minimize pain or inflammatory reactions at the site of administration after administration due to administering a relatively small number of microspheres, and a method for producing the same.
  • an injectable preparation comprising sustained-release microspheres containing leuprolide or a pharmaceutically acceptable salt thereof as an active ingredient and a biocompatible polymer
  • the content of the active ingredient in the injection preparation includes 1 to 50 mg/mL as leuprolide,
  • the injectable preparation may have a number of microspheres of 1,000,000 to 6,000,000/ml.
  • leuprolide or a pharmaceutically acceptable salt thereof in the microspheres may be 9.5 to 40% by weight, 10 to 30% by weight, or 12 to 25% by weight based on the total weight of the microspheres.
  • the biocompatible polymer includes polyethylene glycol-poly(lactide-co-glycolide) block-copolymer, polyethylene glycol-polylactide block-copolymer, and polyethylene glycol-polycaprolactone block-copolymer. It is one or more selected from the group consisting of polymer, polylactide, polyglycolide, poly(lactide-co-glycolide), poly(lactide-co-glycolide)glucose, polycaprolactone, and mixtures thereof. You can.
  • the biocompatible polymer in the microspheres may be 70 to 90% by weight, 75 to 90% by weight, or 80 to 90% by weight based on the total weight of the microspheres.
  • the weight ratio of the active ingredient to the biocompatible polymer in the microspheres may be 1:4 to 1:9, 1:3.5 to 1:9, or 1:3 to 1:9.
  • the biocompatible polymer may be a combination of polymers of the same type having different intrinsic viscosity and/or monomer ratios.
  • the pharmaceutically acceptable salt of leuprolide may be leuprolide acetate.
  • the weight average molecular weight of the biocompatible polymer may be 4,000 to 240,000.
  • the in vitro release rate of the injectable formulation may be 8 to 40%, more specifically 10 to 30%, 24 hours after release of the active ingredient.
  • the injectable formulation may be for a 1-month to 3-month formulation.
  • the cumulative drug area under the curve up to 24 hours after administration is the cumulative drug area under the curve up to the target administration period (AUC 0-24hrs, Area under the curve)
  • AUC total that is, for a 1-month formulation, AUC total is the area under the cumulative drug curve from 0 to 28 days after administration, and for a 3-month formulation, AUC total refers to the area under the cumulative drug curve from 0 to 84 days after administration. It may be 0.5 to 55%, 15 to 50%, or 20 to 50% of the total.
  • the ratio of the area under the cumulative drug curve at 0 to 24 hours after administration to the area under the cumulative drug curve at 48 hours to 168 hours after administration is 2:1 to 10:1, preferably 2:1 to 8:1, more preferably It may be 2:1 to 6:1.
  • the residual solvent in the sustained-release microspheres of the injectable formulation may be less than 1,000 ppm.
  • the C max of the drug after administration of the injection preparation may be 5,000 to 2,000,000 pg/mL.
  • the particle size (D50) of the sustained-release microspheres in the injection preparation may be 10 to 40 um.
  • the injectable preparation reduces fibroid nuclei and improves symptoms in uterine fibroids accompanied by endometriosis, hypermenorrhea, lower abdominal pain, back pain, and anemia, prostate cancer, premenopausal breast cancer, or central precocious puberty. It may be for prevention or treatment.
  • a method for producing sustained-release microspheres containing leuprolide or a pharmaceutically acceptable salt thereof comprising the following steps:
  • a) (i) prepare a dispersed solution by dissolving the biocompatible polymer and leuprolide or a pharmaceutically acceptable salt thereof in one or more organic solvents, or (ii) prepare an oil phase by dissolving the biocompatible polymer in one or more organic solvents.
  • Prepare a solution for the oil phase prepare an aqueous solution by dissolving leuprolide or a pharmaceutically acceptable salt thereof in an aqueous solvent, and add the aqueous solution to the oil phase solution to form a water-in-oil (W/O) solution.
  • step b) The dispersion solution or water-in-oil emulsion prepared in step a) is added to an aqueous solution containing a surfactant as a continuous phase to form microspheres, and the dispersion solution or water-in-oil emulsion is injected and stirred to solidify the microspheres.
  • step b) extracting the organic solvent by adding an aqueous solution containing ethanol and a surfactant to the suspension containing the solidified microspheres of step b);
  • step d) exchanging the continuous phase in the suspension containing the microspheres of step c) with an aqueous solution containing fresh ethanol and a surfactant and stirring;
  • a method for producing sustained-release microspheres containing leuprolide or a pharmaceutically acceptable salt thereof comprising the following steps:
  • a' (i) dissolving the biocompatible polymer and leuprolide or a pharmaceutically acceptable salt thereof in one or more organic solvents to prepare a dispersion solution, or (ii) dissolving the biocompatible polymer in one or more organic solvents to prepare a dispersion solution.
  • a solution for the oil phase was prepared, and leuprolide or a pharmaceutically acceptable salt thereof was dissolved in an aqueous solvent to prepare an aqueous solution, and the aqueous solution was added to the oil phase solution to form a water-in-oil type (W/ O) preparing an emulsion;
  • step b' The dispersion solution or water-in-oil emulsion prepared in step a') is added to an aqueous solution containing ethanol and a surfactant as a continuous phase to form microspheres, and the microspheres are solidified after injection of the dispersion solution or water-in-oil emulsion. and preparing a suspension containing microspheres by stirring for organic solvent extraction;
  • step b' exchanging the continuous phase in the suspension containing the microspheres of step b') with an aqueous solution containing fresh ethanol and a surfactant and stirring;
  • sustained-release microspheres containing leuprolide unlike the conventional production method, it is possible to produce sustained-release microspheres containing leuprolide at a high encapsulation rate, allowing the drug to be contained for a long time. It is possible to manufacture microspheres that maximize the therapeutic effect by maintaining the concentration in the therapeutic range.
  • Figure 1 is a graph showing the in vivo pharmacokinetics of microspheres for a 1-month formulation according to the present invention (Example 1) and Leuprin 3.75 mg (Comparative Example 1), a reference drug.
  • Figure 2 is a graph showing the in vivo pharmacokinetics of microspheres for a 3-month formulation (Examples 5 and 6) according to the present invention.
  • Figures 3a and 3b are scanning electron microscope photographs confirming the shape of microspheres of an example according to the present invention.
  • Figures 4A to 4C are diagrams showing the histopathology slide samples of Example 4 and Comparative Example 2 showing the infiltration of inflammatory cells at the injection site by extracting tissues on the 3rd, 10th, and 28th days after administration of microspheres.
  • the present invention is an injectable preparation comprising sustained-release microspheres containing leuprolide or a pharmaceutically acceptable salt thereof as an active ingredient and a biocompatible polymer,
  • the content of the active ingredient in the injection preparation includes 1 to 50 mg/mL as leuprolide,
  • the present invention relates to an injectable preparation in which the number of microspheres in the injectable preparation is 1,000,000 to 6,000,000/mL.
  • the content of the active ingredient in the injection preparation is leuprolide, 2 to 50 mg/mL, 2 to 47 mg/mL, 2 to 45 mg/mL, 2 to 30 mg/mL, 2 to 27.5 mg/mL, 2 to 5 mg/mL. It may be 25 mg/mL, 3 to 25 mg/mL, or 3 to 22.5 mg/mL.
  • the injectable preparation is a 1-month preparation, it may be 1 to 15 mg/mL, 1 to 12.5 mg/mL, or 2 to 12.5 mg/mL, and if the injectable preparation is a 3-month preparation, it may be 7 to 30 mg/mL, 9 It may be from 27.5 mg/mL or 10 to 25 mg/mL, and for a 6-month preparation, it may be 20 to 50 mg/mL, 20 to 47.5 mg/mL, 25 to 45 mg/mL, 30 to 50 mg/mL, 30 to 47.5 mg/mL. mL, or 30 to 45 mg/mL.
  • the number of microspheres in the injection preparation is 1,000,000 to 5,000,000/ml, 1,200,000 to 4,500,000/ml, 1,000,000 to 4,000,000/ml, 1,200,000 to 3,500,000/ml or 1,500,000. It may be 0 to 3,000,000/mL. More specifically, if the injectable preparation is a 1-month preparation, it may be 1,000,000 to 2,500,000 units/mL or 1,500,000 to 2,000,000 units/mL, and if the injectable preparation is a 3-month preparation, it may be 2,000,000 to 3,500,000 units/mL or 2,500,000 to 3,000, 000 units/mL , if the injectable preparation is a 6-month preparation, it may be 3,000,000 to 6,000,000 units/mL, 3,500,000 to 5,500,000 units/mL, or 4,000,000 to 5,000,000 units/mL.
  • the present invention unlike conventional leuprolide-containing microspheres and preparations containing the same, contains a high content of the active ingredient leuprolide or a pharmaceutically acceptable salt thereof in the microspheres, thereby providing an effective level of effective pharmacological effect. It is characterized by containing a sufficient number of ingredients, while allowing a significantly small number of microspheres per unit volume of the injectable preparation to be included in the injectable preparation. Due to these characteristics, the injectable formulation according to the present invention not only exhibits effective drug release characteristics initially and provides stable drug release characteristics for a long period of time, but also provides stable drug release characteristics for a long period of time, and by administering a relatively small number of microspheres, It can minimize pain or inflammatory reactions.
  • 'leuprolide' is 5-oxo-L-prolyl-L-histidyl-L-tryptophanyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L -Arginyl-L-prolyl ethylamide is an LHGH agonist.
  • the leuprolide may be expressed as leuprorelin. Additionally, in the present invention, all pharmaceutically acceptable salts of leuprolide can be used.
  • 'pharmaceutically acceptable means that it is physiologically acceptable and does not usually cause allergic reactions or similar reactions when administered to humans.
  • 'pharmaceutically acceptable salt' refers to an acid addition salt formed from a pharmaceutically acceptable free acid.
  • Organic acids and inorganic acids can be used as the free acids.
  • the organic acids are not limited thereto, but include citric acid, acetic acid, lactic acid, tartaric acid, maleic acid, fumaric acid, formic acid, propionic acid, oxalic acid, trifluoroacetic acid, benzoic acid, gluconic acid, metasulfonic acid, glycolic acid, succinic acid, 4-toluenesulfonic acid, Includes glutamic acid and aspartic acid.
  • the inorganic acids include, but are not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, and phosphoric acid.
  • the pharmaceutically acceptable salt of leuprolide of the present invention may be leuprolide acetate.
  • the leuprolide or a pharmaceutically acceptable salt thereof may be used in an amount of 9.5 to 40% by weight, 10 to 30% by weight, or 12 to 25% by weight based on the total weight of the microspheres.
  • the biocompatible polymer is polyethylene glycol-poly(lactide-co-glycolide) block-copolymer, polyethylene glycol-polylactide block-copolymer, polyethylene glycol-polycaprolactone block-copolymer, At least one selected from the group consisting of polylactide, polyglycolide, poly(lactide-co-glycolide), poly(lactide-co-glycolide)glucose, polycaprolactone, and mixtures thereof. It may be from 3 types, 1 to 2 types, or 2 to 3 types.
  • “Two or more types of biocompatible polymers” means a combination or blend of different types of biocompatible polymer materials (for example, a blend of poly(lactide-co-glycolide) and polylactide).
  • a combination of polymers of the same type with different intrinsic viscosity, molecular weight, and/or monomer ratio e.g., poly(lactide-co-) with a molar ratio of lactide to glycolide of 40:60
  • it may be the same type of polymer with different end groups (for example, an ester end group or an acid end group).
  • Examples of commercially available biocompatible polymers that can be used in the present invention include RG 502H, RG 503H, RG 504H, RG 502, RG 503, RG 504, and RG 653H from the Resomer series of Evonik Rohm GmbH.
  • the biocompatible polymer may preferably be polylactide.
  • biocompatible polymer being a combination (blend) of two or more types of polymers
  • polylactide is contained at least 50%.
  • the molar ratio of lactide to glycolide in the polymer is 40:60 to 90:10, 45:55 to 85:15, or 50:50 to 75:25, For example, it could be 45:55, 50:50, 75:25, or 85:15.
  • the intrinsic viscosity of the poly(lactide-co-glycolide) or polylactide is 0.16 dL/g to 1.7 dL/g, 0.16 dL/g to 1.5 dL/g, and 0.16 dL/g to 1.2 dL/g. , 0.16 dL/g to 0.9 dL/g, 0.16 dL/g to 0.6 dL/g, 0.16 dL/g to 0.4 dL/g, 0.2 dL/g to 1.3 dL/g, 0.2 dL/g to 1.0 dL/g.
  • 0.2 dL/g to 0.7 dL/g 0.2 dL/g to 0.5 dL/g, 0.24 dL/g to 1.2 dL/g, 0.24 dL/g to 0.7 dL/g, or 0.24 dL/g to 0.5 dL/. It may be g.
  • the intrinsic viscosity of poly(lactide-co-glycolide) or polylactide used in the present invention is measured at a concentration of 0.1% (w/v) in chloroform at 25°C using an Ubbelohde viscometer. . If the intrinsic viscosity of poly(lactide-co-glycolide) or polylactide is less than 0.16 dL/g, the molecular weight of the polymer is insufficient, making it difficult to exhibit the sustained-release effect of leuprolide or a pharmaceutically acceptable salt thereof. , if the intrinsic viscosity exceeds 1.7 dL/g, the release of leuprolide or a pharmaceutically acceptable salt thereof may be delayed too much. In addition, when manufacturing microspheres using a polymer with high intrinsic viscosity, there is a problem of having to use an excessive amount of production solvent due to the high viscosity of the polymer, and it is difficult to manufacture reproducible microspheres.
  • the weight average molecular weight of the biocompatible polymer is not particularly limited, but may have a weight average molecular weight of 4,000 to 240,000.
  • the weight average molecular weight of the biocompatible polymer is 4,000 to 100,000, 7,000 to 50,000, 5,000 to 20,000, 10,000 to 18,000, and 18,000 to 28,000. Includes all lower numerical ranges within the above range, such as average molecular weight.
  • the biocompatible polymer in the microspheres may be 70 to 90% by weight, 75 to 90% by weight, or 80 to 90% by weight based on the total weight of the microspheres.
  • the weight ratio of the active ingredient to the biocompatible polymer in the microspheres may be 1:4 to 1:9, 1:35 to 1:9, or 1:3 to 1:9.
  • the sustained-release microspheres containing leuprolide or a pharmaceutically acceptable salt thereof of the present invention may have a particle diameter (D50) of 10 to 40 ⁇ m.
  • the sustained-release microspheres prepared according to the production method according to the present invention may have a significant amount of residual solvent removed compared to the prior art.
  • the residual solvent in the microspheres may be less than 1000 ppm, less than 900 ppm, or 800 ppm. It may be less than, less than 700 ppm, less than 600 ppm, 1000 to 0.01 ppm, 900 to 0.01 ppm, 800 to 0.01 ppm, 700 to 0.01 ppm, or 600 to 0.01 ppm.
  • the sustained-release microspheres may be suitable for a 1-month to 3-month formulation.
  • the sustained-release microspheres may have an in vitro release rate of 8 to 40% or 10 to 30% 24 hours after release of the active ingredient.
  • the sustained-release microspheres may have a C max of 20,000 to 2,000,000 pg/mL after being administered to rats as an active ingredient at a dose of 1.5 mg/head for 1 month (4 weeks).
  • the C max of the drug may be 20,000 to 900,000 pg/mL
  • the C max of the drug may be 50,000 to 2,000,000 pg/mL.
  • the cumulative drug area under the curve up to 24 hours after administration is the cumulative drug area under the curve up to the target administration period (AUC) total , for a 1-month formulation, the area under the cumulative drug curve up to 28 days after drug administration; for a 3-month formulation, the cumulative area under the drug curve up to 84 days after drug administration; and for a 6-month formulation, the area under the cumulative drug curve up to 168 days after drug administration. It may be 0.5 to 55%, 0.6 to 50%, or 0.7 to 50% of the cumulative drug curve area.
  • the cumulative area under the drug curve up to 24 hours after administration (AUC 0-24hrs , Area under the curve ) is 12. It may be from 45% to 45%, 20 to 42% or 30 to 40%.
  • the cumulative area under the drug curve up to 24 hours after administration (AUC 0-24hrs , Area under the curve) is 30 to 55% or 35% of the cumulative area under the curve until the target administration period (AUC total ). It may be from 40 to 53%, or from 40 to 50%.
  • the cumulative area under the drug curve up to 24 hours after administration (AUC 0-24hrs , Area under the curve ) is 0.5 to 55%, 0.6%. It may be from 0.7 to 50% or from 0.7 to 50%.
  • the ratio of the area under the cumulative drug curve at 0 to 24 hours after administration to the area under the cumulative drug curve at 48 hours to 168 hours after administration is 2:1 to 10:1, preferably 2:1 to 8:1, more preferably 2. :1 to 6:1.
  • sustained-release microspheres according to the present invention when administered in vivo as described above, exhibit the ratio of the area under the cumulative drug curve at 0 to 24 hours after administration: the area under the cumulative drug curve at 48 hours to 168 hours after administration, Not only does it ensure sufficient initial release of leuprolide or a pharmaceutically acceptable salt thereof, but also maintains the efficacy of the active ingredient for a desired period of time, for example, 1 month or more, 3 months or more, 1 month to 3 months, etc. Enable continuous and sufficient performance.
  • a) (i) prepare a dispersed solution by dissolving the biocompatible polymer and leuprolide or a pharmaceutically acceptable salt thereof in one or more organic solvents, or (ii) prepare an oil phase by dissolving the biocompatible polymer in one or more organic solvents.
  • Prepare a solution for the oil phase prepare an aqueous solution by dissolving leuprolide or a pharmaceutically acceptable salt thereof in an aqueous solvent, and add the aqueous solution to the oil phase solution to form a water-in-oil (W/O) solution.
  • step b) The dispersion solution or water-in-oil emulsion prepared in step a) is added to an aqueous solution containing a surfactant as a continuous phase to form microspheres, and the dispersion solution or water-in-oil emulsion is injected and stirred to solidify the microspheres.
  • step b) extracting the organic solvent by adding an aqueous solution containing ethanol and a surfactant to the suspension containing the solidified microspheres of step b);
  • step d) exchanging the continuous phase in the suspension containing the microspheres of step c) with an aqueous solution containing fresh ethanol and a surfactant and stirring;
  • e relates to a manufacturing method comprising the step of recovering microspheres.
  • the present invention provides another method for producing sustained-release microspheres containing leuprolide or a pharmaceutically acceptable salt thereof,
  • a' (i) dissolving the biocompatible polymer and leuprolide or a pharmaceutically acceptable salt thereof in one or more organic solvents to prepare a dispersion solution, or (ii) dissolving the biocompatible polymer in one or more organic solvents to prepare a dispersion solution.
  • a solution for the oil phase was prepared, and leuprolide or a pharmaceutically acceptable salt thereof was dissolved in an aqueous solvent to prepare an aqueous solution, and the aqueous solution was added to the oil phase solution to form a water-in-oil type (W/ O) preparing an emulsion;
  • step b' The dispersion solution or water-in-oil emulsion prepared in step a') is added to an aqueous solution containing ethanol and a surfactant as a continuous phase to form microspheres, and the microspheres are solidified after injection of the dispersion solution or water-in-oil emulsion. and preparing a suspension containing microspheres by stirring for organic solvent extraction;
  • step b' exchanging the continuous phase in the suspension containing the microspheres of step b') with an aqueous solution containing fresh ethanol and a surfactant and stirring;
  • d' relates to a manufacturing method comprising the step of recovering microspheres.
  • microsphere preparations using biocompatible polymers to develop sustained-release preparations have developed into a field of active research interest and clinical application.
  • the drug to be contained in the microspheres must be encapsulated in a high amount considering the administration period and dosage.
  • the present invention is a method for producing sustained-release microspheres containing leuprolide or a pharmaceutically acceptable salt thereof, and is characterized in that ethanol is used without heating to remove the residual solvent of the microspheres.
  • the step a) or a') is a step of preparing (i) a dispersion solution or (ii) a water-in-oil emulsion for producing microspheres.
  • the emulsion prepared in step b) or b') below is an O/W emulsion
  • the water-in-oil emulsion of (ii), step b) or The emulsion prepared in b') may be a W/O/W type emulsion.
  • the biocompatible polymer and leuprolide or a pharmaceutically acceptable salt thereof are dissolved in one or more organic solvents to prepare a dispersed phase solution.
  • the one or more organic solvents may be two or more organic solvents, and one of the two or more organic solvents may be used as a co-solvent.
  • the biocompatible polymer is dissolved in one organic solvent, and leuprolide or a pharmaceutically acceptable salt thereof is dissolved in another organic solvent to prepare each solution, and then mixed to form a dispersed phase. (i) can be performed by obtaining a solution.
  • Step a) or step a') may be performed at 15 to 25°C, or at room temperature.
  • the organic solvent used in steps (i) and (ii) of step a) or a') is dichloromethane, chloroform, ethyl acetate, methyl ethyl ketone, acetone, acetonitrile, dimethyl sulfoxide, dimethyl formamide, It may be at least one solvent selected from the group consisting of enmethylpyrrolidone, acetic acid, methyl alcohol, ethyl alcohol, propyl alcohol, and benzyl alcohol, or a mixed solvent of two or more of the above solvents.
  • the amount of leuprolide or a pharmaceutically acceptable salt thereof is 9 to 40% compared to the total weight (i.e., total solid weight) of the biocompatible polymer and leuprolide or a pharmaceutically acceptable salt thereof to be prepared. It may be used in weight percent, 10 to 35 weight percent, or 12 to 25 weight percent.
  • biocompatible polymer may be applied to the injectable preparation containing the sustained-release microspheres, unless otherwise defined.
  • the method for producing leuprolide sustained-release microspheres according to the present invention is b) or b') adding the dispersed phase solution or water-in-oil emulsion prepared in step a) or a') to an aqueous solution containing a surfactant as a continuous phase.
  • This includes forming microspheres, and after completing the injection of the dispersion acid solution or water-in-oil emulsion, stirring to solidify the microspheres to prepare a suspension containing the microspheres.
  • the content of the surfactant in the continuous phase containing the surfactant is 0.01% by weight to 20% by weight, preferably 0.1% by weight to 5% by weight, based on the total volume of the continuous phase. You can. If the surfactant content is less than 0.01% by weight, a dispersed phase or emulsion in the form of droplets may not be formed in the continuous phase, and if the surfactant content exceeds 20% by weight, excessive surfactant may cause the formation of a dispersed phase or emulsion in the continuous phase. After the particulates are formed, it may be difficult to remove the surfactant.
  • the surfactant in step b) or b') is methylcellulose, polyvinylpyrrolidone, carboxymethylcellulose, lecithin, gelatin, polyvinyl alcohol, polyoxyethylene sorbitan fatty acid ester, and polyoxyethylene castor oil derivatives, and their It may be one or more types selected from the group consisting of mixtures.
  • the aqueous solvent for preparing the aqueous solution containing the surfactant in step b) or b') is water, or a solvent selected from the group consisting of water and methyl alcohol, ethyl alcohol, propyl alcohol, and ethyl acetate, or a mixed solvent thereof. It may be.
  • the method of homogeneously mixing the biocompatible polymer solution in which leuprolide or a pharmaceutically acceptable salt thereof is dispersed and the continuous phase containing the surfactant is not particularly limited, but includes a high-speed stirrer, It can be performed using an in-line mixer, ultrasonic disperser, static mixer, membrane emulsion method, microfluidics emulsion method, etc.
  • a high-speed stirrer it can be performed using an in-line mixer, ultrasonic disperser, static mixer, membrane emulsion method, microfluidics emulsion method, etc.
  • the stirring process in step b) or b') may be performed for 1 to 5 hours, 2 to 4 hours, or 3 hours for solidification.
  • step b) or b') may be performed at 4 to 24°C, 10 to 17°C, or 15°C.
  • an aqueous solution further containing ethanol in addition to a surfactant may be used as a continuous phase to extract the organic solvent during the formation and solidification of the microspheres.
  • the content of ethanol in the aqueous solution containing ethanol and surfactant is 5 to 40 (v/v)%, 5 to 30 (v/v)%, 5 to 5%, based on the total volume of the aqueous solution. It may be 20(v/v)%, 7 to 40(v/v)%, 7 to 30(v/v)%, 7 to 20(v/v)% or 10 to 20(v/v)%. . If the ethanol content is less than 5(v/v)%, the residual amount of organic solvent may increase, and if it exceeds 30(v/v)%, the encapsulation rate may be reduced or initial release control may be difficult. .
  • step c) an aqueous solution containing ethanol and a surfactant is added to the suspension containing the solidified microspheres prepared in step b) to extract the organic solvent in a continuous phase.
  • the temperature is lower than that of the prior art, at 4 to 24°C, 10 to 17°C, or 15°C for a certain period of time, for example, 1 hour to 48 hours, 5 to 36 hours, or 7 to 15°C.
  • the organic solvent can be effectively extracted from the microspheres by maintaining or stirring for 24 hours, 10 to 20 hours, or 15 hours. Some of the extracted organic solvent may evaporate from the surface of the microspheres.
  • step c) The type of surfactant used in step c) may be the same as that used in step b).
  • the solvent in the aqueous solution of step c) may be water or a mixed solvent of water and one or more solvents selected from the group consisting of methyl alcohol, ethyl alcohol, propyl alcohol, and ethyl acetate.
  • the content of ethanol in the aqueous solution containing ethanol and surfactant is 5 to 40 (v/v)%, 5 to 30 (v/v)%, 5%, based on the total volume of the aqueous solution. to 20 (v/v)%, 7 to 40 (v/v)%, 7 to 30 (v/v)%, 7 to 20 (v/v)% or 10 to 20 (v/v)%. there is. If the ethanol content is less than 5(v/v)%, the residual amount of organic solvent may increase, and if it exceeds 30(v/v)%, the encapsulation rate may be reduced or initial release control may be difficult. .
  • step d) or c' after extracting the organic solvent in step c) or b'), it is exchanged with an aqueous solution containing fresh ethanol and a surfactant and incubated for a certain period of time, specifically 1 hour to 48 hours, 1 hour to 48 hours. Stir for 24 hours, 1 hour to 12 hours, and 1 hour to 5 hours.
  • the holding time may be 3 hours, but is not limited thereto.
  • step e) or d' the microspheres are finally recovered.
  • step e) or d' the method of recovering microspheres according to the present invention may be performed using various known techniques, for example, methods such as filtration or centrifugation may be used.
  • step e) or d' the microsphere suspension upon recovery is further washed with a washing liquid (e.g. water, specifically ultrapure water), preferably repeatedly, to remove residual surfactant.
  • a washing liquid e.g. water, specifically ultrapure water
  • the obtained microspheres are dried using a conventional drying method, for example, freeze-drying, to obtain final dried microspheres.
  • the sustained-release microspheres containing leuprolide or a pharmaceutically acceptable salt thereof prepared by the production method of the present invention may have a particle diameter (D50) of 10 to 40 ⁇ m.
  • the sustained-release microspheres prepared according to the production method according to the present invention may have a significant amount of residual solvent removed compared to the prior art.
  • the residual solvent in the microspheres may be less than 1000 ppm.
  • the encapsulation rate of the prepared sustained-release microspheres is 60% or more, 60 to 100%, 70% or more, 70 to 100%, 75% or more, 75 to 100%, 75 to 98%, or 75%. It may be from 95% to 95%. Preferably, it may be 80% or more, 80 to 100%, 80 to 98%, 90 to 100%, 95 to 100%, or 80 to 95%.
  • microspheres of leuprolide or a pharmaceutically acceptable salt thereof were prepared.
  • the dispersed phase is a mixture of biocompatible polymers PLGA or PLA and leuprolide acetate (manufacturer: Polypeptide Laboratories Pvt, Ltd., India) with dichloromethane (manufacturer: J.T Baker, USA) and methyl alcohol (manufacturer: Tedia Company, USA). Alternatively, it was mixed with ethyl acetate (manufacturer: Junsei chemical Co. Ltd., Japan) and methyl alcohol (manufacturer: Tedia Company, USA) and dissolved until it became transparent to the naked eye.
  • a 1.0% (w/v) polyvinyl alcohol (viscosity: 4.8-5.8 mPa ⁇ s) aqueous solution was used as the continuous phase, and the continuous phase was connected to an emulsifier equipped with a porous membrane and the prepared dispersed phase was injected to prepare microspheres. did.
  • the temperature of the membrane emulsification device, preparation vessel, and microsphere suspension was maintained at 15°C, and after dispersion phase injection was completed, it was stirred at 200 rpm for 3 hours. Ethanol was added and stirred for 18 hours to extract the organic solvent, and then stirred in the same continuous phase for 3 hours.
  • the microsphere suspension was washed several times with ultrapure water to remove residual polyvinyl alcohol, and the microspheres were recovered by lyophilization.
  • Example 4 R202H 20 DCM MeOH PVA Solvent Extraction (10% EtOH) 15
  • Example 5 R202H 20 DCM MeOH PVA Solvent Extraction (20% EtOH) 15
  • Leuprolide microspheres that did not use the ethanol process for organic solvent extraction were prepared by the following method.
  • the dispersed phase is a mixture of biocompatible polymers PLGA or PLA and leuprolide acetate (manufacturer: Polypeptide Laboratories Pvt, Ltd., India) with dichloromethane (manufacturer: J.T Baker, USA) and methyl alcohol (manufacturer: Tedia Company, USA). It was dissolved until it became transparent to the naked eye. A 0.5% (w/v) polyvinyl alcohol (viscosity: 4.8-5.8 mPa ⁇ s) aqueous solution was used as the continuous phase, and the continuous phase was connected to an emulsifier equipped with a porous membrane and the prepared dispersed phase was injected to prepare microspheres. did.
  • the temperature of the membrane emulsification device, preparation vessel, and microparticle suspension was maintained at 25°C, and after the injection of the dispersed phase was completed, the organic solvent was removed while maintaining the temperature of the microparticle suspension at 36°C for 3 hours. After removal of the organic solvent, the temperature of the microparticle suspension was lowered to 25°C. The microsphere suspension was washed several times with ultrapure water to remove residual polyvinyl alcohol, and the microspheres were freeze-dried.
  • Leuprolide microspheres that did not use the ethanol process for organic solvent extraction were prepared by the following method.
  • the dispersed phase was prepared by dissolving the biocompatible polymers PLGA or PLA and leuprolide acetate (manufacturer: Polypeptide Laboratories Pvt, Ltd., India) in dichloromethane (manufacturer: J.T Baker, USA) and distilled water, respectively, to prepare an oil phase and an aqueous phase.
  • a W/O emulsion was formed by emulsifying at 12,000 rpm using an IKA homogenizer.
  • a 0.5% (w/v) polyvinyl alcohol (viscosity: 4.8-5.8 mPa ⁇ s) aqueous solution was used as the continuous phase, and microspheres were prepared by connecting the continuous phase to an emulsifier equipped with a porous membrane and simultaneously injecting the prepared dispersed phase. .
  • the temperature of the membrane emulsification device, preparation vessel, and microparticle suspension was maintained at 25°C, and after the injection of the dispersed phase was completed, the microparticle suspension was heated and maintained for 3 hours to remove the organic solvent. After removal of the organic solvent, the temperature of the microparticle suspension was lowered to 25°C.
  • the microsphere suspension was washed several times with ultrapure water to remove residual polyvinyl alcohol, and the microspheres were freeze-dried.
  • microspheres prepared in the above example 10 mg were completely dissolved in 2.5 mL of acetonitrile, and then extracted by adding 7.5 mL of 0.1% (w/w) trifluoroacetic acid aqueous solution. The solution filtered using a 0.45 um filter was used as the test solution. 20uL of the test solution was injected into the HPLC and measured at a detection wavelength of 280nm. The column used in this measurement was Inertsil ODS-3, 5 um, 4.6x150 mm, and the mobile phase was acetonitrile containing 0.1% (w/w) trifluoroacetic acid and 0.1% (w/w) trifluoroacetic acid. Acetic acid aqueous solution was mixed and used at a ratio of 25:75 (v/v). The measured encapsulation amounts are shown in Table 3.
  • a test was conducted using laser diffraction to quantitatively measure the average particle size, distribution, and uniformity of microspheres.
  • Example 2 32.45 E.E 91.2% DC 13.67%
  • Example 3 27.64 E.E 79.6% DC 15.92% 3 months
  • the following experiment was performed to confirm the initial drug release of the microspheres prepared in the above Examples and Comparative Examples. Place 10 mg of microspheres in an HDPE wide-mouth bottle, fill with 50 mL of release test solution, and store in an incubator at 37°C. After 24 hours, 1 mL of this sample solution was taken and centrifuged, and the obtained supernatant was analyzed for leuprolide content and release rate using HPLC under the same analysis conditions as in Experimental Example 1.
  • the release test solution for this measurement was a pH 7.4 aqueous solution containing phosphate and sodium azide.
  • Pharmacokinetic evaluation was performed on the microspheres of Examples and Preparation Examples using 9-week-old SD (Sprague-Dawly) rats.
  • the microsphere injection preparations of Examples and Preparation Examples in rats were measured at a dose of 1.5 mg/head as an active ingredient for 1 month (4 weeks) in rats, suspended in 0.3 mL dispersion solvent, and then subcutaneously injected into SD rats. . 0.25 to 0.5 mL of blood was collected at pre-planned times, and blood leuprolide concentration was measured using LC-MS/MS. The measurement results are shown in Table 5 and Figures 1 (1-month formulation) and Figure 2 (3-month formulation).
  • the morphological characteristics of the microspheres according to the present invention were analyzed through electron microscopy.
  • the experimental procedure is as follows. 5 mg of microspheres prepared in Examples and Preparation Examples were placed on an aluminum stub with carbon tape attached and coated with platinum using ION-COATER (COXEM, Korea). An aluminum stub was mounted on a scanning electron microscope (COXEM EM-30, Korea), and the morphological characteristics of the microspheres were observed at an acceleration voltage of 10 ⁇ kV. The results are shown in Figures 3a (1-month formulation) and 3b (3-month formulation).
  • microspheres according to the present invention have excellent storage stability and safety to the human body due to the low residual solvent amount of less than 1000 ppm.
  • the particle number of microspheres according to the present invention was measured as follows. The number of microspheres was confirmed by directly checking the number of particles using an optical microscope. 10 mg of microspheres prepared in Examples and Comparative Examples were weighed and dispersed in 0.5 (w/w)% PVA. At this time, the comparative example containing 15 (w/w)% mannitol was performed by correcting the weight (weight correction was performed by weighing 11.8 mg so that the weight of the microspheres was 10 mg when mannitol was excluded). The microspheres dispersed in 0.5 (w/w)% PVA were diluted with 0.5 (w/w)% PVA so that the concentration was 0.1 mg/mL. 10 ⁇ m of the diluted 0.1 mg/mL concentration microsphere solution was taken and the number of particles was confirmed under a microscope.
  • the administration dose was adjusted so that the content of the active ingredient (API) in the examples and comparative examples was the same, and is shown in Tables 7 and 8.
  • Table 7 shows the 1-month formulation
  • Table 8 shows the 3-month formulation.
  • Example 2 Based on one administration Example 2 Comparative Example 1 (Leuplin 3.75mg) API concentration (mg/mL) 3.75 3.75 Microparticle concentration (mg/mL) 27.4 44.1 Number of microspheres (piece/mg) 67,000 149,300 Number of administered microspheres (number/mL) 1,836,623 6,586,765
  • Example 4 Based on one administration Example 4 Comparative Example 2 (Leuplin 11.25mg) API concentration (mg/mL) 11.25 11.25 Microparticle concentration (mg/mL) 58.9 130.1 Number of microspheres (piece/mg) 49,700 262,300 Number of administered microspheres (number/mL) 2,927,356 34,114,162
  • the conventional injection preparation containing leuprolide has a microparticle concentration that is 1.6 to 2.2 times higher than the injection preparation according to the present invention. With this, it was confirmed that the number of microspheres was also 3.6 to 11.7 times greater. This has the advantage that the injection preparation according to the present invention has a significantly lower number and concentration of microspheres compared to the same active ingredient content, and can reduce various problems that may occur due to a large number of microspheres and a high concentration of microspheres upon administration, such as the level of inflammation. You can have it.
  • Example 4 The degree of inflammation at the administration site when the microspheres prepared in Example 4 and Comparative Example 2 were administered was confirmed.
  • 0.5 mL of suspension (Diluent) 0.5(w/w)% NaCMC, 5(w/w)% Mannitol, 0.1(w/w)% Tween 80
  • the microspheres were added. Mix well until completely dispersed.
  • the microspheres were administered subcutaneously to the back of SD rats at a dose of 4.5mg/head. Tissues were removed on the 3rd, 10th, and 28th days after administration and analysis of inflammation at the administration site was performed, which is shown in Table 9.
  • Example 4 (SD rat, male 8 weeks old) At each confirmation time, histopathology slide samples of Example 4 and Comparative Example 2 were prepared, stained with H&E (Hematoxylin and Eosin), and inflammatory cell infiltration was confirmed. Photographs of samples stained in this way are shown in Figures 4a (3 days), 4b (10 days), and 4c (28 days). Yellow circles represent infiltrated cells, red arrows represent angiogenesis, and blue arrows represent fibrous tissue formation.
  • H&E Hematoxylin and Eosin
  • Table 10 is a table that quantifies the degree of inflammatory cell infiltration on the 3rd, 10th, and 28th days after administration of microspheres to SD rats.
  • Inflammatory cell infiltration is graded from 0 to 3 by randomly selecting three parts at 400x field of view (HPF), counting the number of cells.
  • HPF 400x field of view
  • Example 4 On the 3rd day after microball administration, the inflammatory response was strong in both Example 4 and Comparative Example 2, so no significant difference could be confirmed, but on the 10th and 28th day after microball administration, the inflammatory response was strong. While the inflammatory response continued in Example 2, it was confirmed that the inflammatory response was relatively reduced in Example 4.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pain & Pain Management (AREA)

Abstract

La présente invention concerne des microsphères à libération prolongée contenant une quantité élevée de leuprolide, une préparation injectable la comprenant, et un procédé de préparation associé. Pendant l'administration, le leuprolide est libéré à un niveau suffisant à une étape précoce de telle sorte que les effets du leuprolide sont présentés, ce qui permet une exposition à une quantité suffisante d'un médicament tandis que des réactions inflammatoires et similaires, qui peuvent être problématiques pendant l'administration, sont réduites à un minimum, et ainsi les effets du leuprolide peuvent être présentés en toute sécurité au moins 1 mois.
PCT/KR2023/013112 2022-09-01 2023-09-01 Microsphères à libération prolongée contenant du leuprolide, préparation injectable les comprenant, et leur procédé de préparation WO2024049279A2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
KR20220110883 2022-09-01
KR10-2022-0110883 2022-09-01
KR20220147421 2022-11-07
KR10-2022-0147421 2022-11-07
KR1020230059471A KR20240031868A (ko) 2022-09-01 2023-05-08 류프롤라이드를 포함하는 서방형 미립구, 이를 포함하는 주사제제 및 이의 제조방법
KR10-2023-0059471 2023-05-08

Publications (1)

Publication Number Publication Date
WO2024049279A2 true WO2024049279A2 (fr) 2024-03-07

Family

ID=90098380

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2023/013112 WO2024049279A2 (fr) 2022-09-01 2023-09-01 Microsphères à libération prolongée contenant du leuprolide, préparation injectable les comprenant, et leur procédé de préparation

Country Status (1)

Country Link
WO (1) WO2024049279A2 (fr)

Similar Documents

Publication Publication Date Title
WO2011081406A2 (fr) Macromolécule pour administration de médicaments protéiques, polypeptidiques pou peptidiques et son procédé de fabrication, et composition à libération lente pour protéine, peptide ou médicaments protéiques, polypeptidiques ou peptidiques, et son procédé de fabrication
WO2019078583A1 (fr) Microparticules à libération prolongée comprenant un médicament, et procédé de préparation associé
WO2020197190A1 (fr) Procédé de préparation de microsphères chargées d'apixaban à base de polymère biocompatible
US10478470B2 (en) Pharmaceutical composition containing leuprolide and having both immediate and sustained release properties
WO2020040438A1 (fr) Préparation pharmaceutique ayant d'excellentes propriétés de dissolution, contenant de l'ésoméprazole et du bicarbonate de sodium
WO2021010719A1 (fr) Formulation à longue durée d'action contenant de la rivastigmine et son procédé de préparation
WO2021162532A2 (fr) Composition pharmaceutique comprenant des microsphères à libération prolongée comportant un analogue de glp -1 ou un sel pharmaceutiquement acceptable de celui-ci
WO2021091246A1 (fr) Microsphères à libération prolongée en mesure de réguler la libération initiale et procédé de préparation associé
WO2018147660A1 (fr) Préparation d'administration de médicament pour le traitement de maladies mentales ou de troubles du système nerveux central
EP3946273A1 (fr) Compositions de phase dispersée pour la préparation de microsphères chargées d'apixaban et microsphères chargées d'apixaban à base de polymère biocompatible préparées à partir de celles-ci
WO2016114521A1 (fr) Composition de dutastéride sous forme de comprimé présentant une stabilité améliorée
WO2022010317A1 (fr) Procédé de préparation de microsphères de plga à libération prolongée contenant du donépézil
WO2022050783A1 (fr) Microparticules à libération prolongée pour la libération prolongée de médicament
WO2024049279A2 (fr) Microsphères à libération prolongée contenant du leuprolide, préparation injectable les comprenant, et leur procédé de préparation
WO2020130585A1 (fr) Injection à libération prolongée comprenant de la desloréline, et son procédé de préparation
WO2016036093A1 (fr) Film dispersible oral de tadalafil et son procédé de préparation
WO2023101348A1 (fr) Microparticules contenant du leuprolide, et leur procédé de préparation
WO2012087051A2 (fr) Microparticules contenant un peptide physiologiquement actif, procédé pour les préparer et composition pharmaceutique les contenant
WO2020242234A1 (fr) Composition injectable contenant un promédicament d'inhibiteurs de caspase, et son procédé de préparation
WO2023038202A1 (fr) Microsphère à libération prolongée utilisant un polymère biodégradable et procédé pour sa préparation
WO2019208982A1 (fr) Procédé de préparation de microshères biodégradables à l'aide d'une solution de mélange à phase unique stabilisée
WO2021167364A1 (fr) Composition pharmaceutique comprenant de l'ésoméprazole et du bicarbonate de sodium présentant d'excellentes propriétés de libération
WO2023249464A1 (fr) Microparticules à libération prolongée contenant un médicament et de l'acide pamoïque
WO2024101859A1 (fr) Préparation injectable à libération prolongée comprenant de l'acétate de dexaméthasone et procédé de préparation s'y rapportant
WO2022005169A1 (fr) Composition injectable comprenant des dérivés de gnrh

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23860954

Country of ref document: EP

Kind code of ref document: A2